Member

BioVersys AG

Hochbergerstrasse 60C

The biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company’s award-winning TRIC technology (Transcriptional Regulator Inhibitory Compounds) it is possible to restore the efficacy of approved antibiotics. By this, BioVersys addresses the high medical need for new treatments against life-threatening infections that emerged in recent years due to the resistance of bacterial strains against existing antibiotics. The current research focus is Nosocomial Infections (hospital acquired infections) and Tuberculosis. In collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, BioVersys is developing a preclinical candidate for the treatment of multidrug-resistant tuberculosis.

BioVersys AG

Hochbergerstrasse
4057 Basel
Switzerland


Sectores
Chemical & Pharmaceutical Technology
Bio Technology (Biotech)
Life Science
Country of Origin
Suiza
Compartir